États-Unis · Plateformes & données · The Motley Fool

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

Publié par The Motley Fool · États-Unis il y a 44 min

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? — Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? · The Motley Fool

Résumé détaillé

Bristol Myers trades at under 10 times forward earnings, while Vertex commands nearly triple that multiple, but its margins are roughly double.

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

À lire aussi

How much in Roth conversions can you do in 2027 with the new tax brackets?

Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline

Heavy rain floods tents housing Gaza displaced people, aid shortages hamper response

Best Stocks Under $5

Just 13.8% of American Families Own a Second Home or Other Residential Property. The Typical One Is Worth $280,000

Fed rate call leaves stock investors watching December closely